A Phase 2 Multicenter, Randomized, Placebo Controlled, Double Blind Study to Assess the Safety and Efficacy of CC-486 (Oral Azacitidine) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo in Subjects With Previously Treated Locally Advanced or Metastatic Non-small Cell Lung Cancer

Trial Profile

A Phase 2 Multicenter, Randomized, Placebo Controlled, Double Blind Study to Assess the Safety and Efficacy of CC-486 (Oral Azacitidine) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Plus Placebo in Subjects With Previously Treated Locally Advanced or Metastatic Non-small Cell Lung Cancer

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs Azacitidine (Primary) ; Pembrolizumab
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 21 Jul 2017 Planned End Date changed from 30 Jun 2017 to 26 Jan 2018.
    • 03 May 2017 Planned End Date changed from 1 May 2017 to 30 Jun 2017.
    • 28 Jul 2016 According to a Celgene Corporation media release, status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top